Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RAC1 | P63000 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19161966 | 0.86 | ATM (0.38) | ELANETNKSTNKS2TNFNOD1 | |
| SCHEMBL19161279 | 0.85 | ATM (0.39) | ELANESMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL24627103 | 0.85 | TNF (0.45) | ELANETNKSTNKS2TNFNOD1 | |
| SCHEMBL24627159 | 0.84 | ABCG2 (0.40) | ELANETNKSTNKS2TNFNOD1 | |
| SCHEMBL19169496 | 0.83 | ELANE (0.40) | ELANEARAURKAAURKBCYP1A2 | |
| SCHEMBL19169384 | 0.81 | ELANE (0.38) | ELANEARAURKAAURKBCYP1A2 | |
| SCHEMBL19660799 | 0.81 | ALDH1A1 (0.38) | ELANEARAURKAAURKBCYP1A2 | |
| SCHEMBL24627143 | 0.81 | ELANE (0.36) | ELANETNKSTNKS2TNFNOD1 | |
| SCHEMBL19161277 | 0.80 | TNKS (0.45) | ARCASRAURKAAURKBTNKS | |
| SCHEMBL18370734 | 0.80 | ADORA2A (0.39) | ELANEAURKAAURKBCYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10580998-B2 | Nitrogen-containing condensed cyclic compound and organic light emitting device using same | LG CHEM, LTD. (KR) | 2020-03-03 | — | — | US | disclosed |
| US-20190173022-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LG CHEM, LTD. (KR) | 2019-06-06 | — | — | US | disclosed |
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LG CHEM, LTD. (KR) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10580998-B2 | Nitrogen-containing condensed cyclic compound and organic light emitting device using same | CRY1, NOS1, NOLC1 | ELANE 2532/4885AR 3056/4885CASR 4605/4885 |
| US-20190173022-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | CRY1, NOS1, NOLC1 | ELANE 2532/4885AR 3056/4885CASR 4605/4885 |
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | CRY1, NOS1, NOLC1 | ELANE 2532/4885AR 3056/4885CASR 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.